Avtor/Urednik		Oblak, Teja; Lindič, Jelka; Gubenšek, Jakob; Kveder, Radoslav; Aleš, Andreja; Škoberne, Andrej; Večerić-Haler, Željka; Borštnar, Špela; Avguštin, Nuša; Ponikvar, Rafael; Mlinšek, Gregor; Ferluga, Dušan; Kojc, Nika; Godnov, Uroš; Kovač, Damjan
Naslov		Treatment of antibody-mediated rejection of kidney grafts with bortezomib and/or rituximab compared to standard regimen
Tip		članek
Vol. in št.		Letnik 88, št. suppl. 1
Leto izdaje		2017
Obseg		str. S91-S96
ISSN		0301-0430 - Clinical nephrology
Jezik		eng
Abstrakt		Background: The aim of our study was to determine outcomes of standard treatment of antibody-mediated rejection (ABMR) of kidney grafts as compared to the addition of bortezomib or rituximab. Methods: The cohort of this retrospective study included patients treated for ABMR of kidney grafts at our national center in the period of 2005 - 2017, divided into two groups: standard (ST) group treated standardly with plasmapheresis or immunoadsorption, intravenous immunoglobulins, and corticosteroids, and BR group treated with the addition of bortezomib and/or rituximab. Patient and graft survival at 2 years was analyzed by Kaplan-Meier method, and predictors of graft survival were analyzed by Cox regression. Results: There were 78 patients with ABMR (48 in the ST group, 30 in the BR group), 41 (53%) were men, mean age 49.5 +- 13.8 years. In ST and BR, respectively, mean serum creatinine was 267 +- 164 and 208 +- 112 [micro]mol/L (p = 0.088), donor-specific antibodies (DSA) were positive in 75% and 97% (p = 0.022), and ABMR was acute in 50% and 33% (p = 0.149). Patient survival at 2 years was 89% in the ST and 100% in the BR group (p = 0.125). Cumulative proportion of kidney graft survival at 1 and 2 years was 67% and 53% in the ST group and 73% and 48% in the BR group, respectively, (p = 0.641). Chronic ABMR (HR 5.22, p = 0.004) was significant, while dialysis dependency at biopsy (HR 3.28, p = 0.072), serum creatinine at kidney biopsy (HR 1.003, p = 0.082), and presence of DQ-DSA (HR 3.37, p = 0.062) were borderline significant predictors of worse graft outcome. Infections were relatively common in both groups, with a trend towards more rehospitalizations due to infections in the first 6 months after treatment in the BR group (p = 0.066). In 5 patients (17%), treatment with bortezomib was discontinued prematurely due to cytopenia. Conclusions: Bortezomib or rituximab, added to standard treatment, did not significantly improve kidney graft survival and was also not associated with significant side effects, except cytopenia in some cases. Treatment of acute ABMR resulted in better graft survival than chronic ABMR.
Proste vsebinske oznake		kidney grafts rejection treatment ledvični presadki zavrnitev zdravljenje